The cytotoxic anti-cancer drugs cisplatin, paclitaxel, doxorubicin, 5-fluorouracil (5-FU), as
well as targeted drugs including imatinib, erlotinib, and nivolumab, play key roles in clinical …

A veritable explosion of primary research papers within the past 10 years focuses on
nucleolar and ribosomal stress, and for good reason: with ribosome biosynthesis …

Inactivation of the tumor suppressor p53 by missense mutations is the most frequent genetic
alteration in human cancers. The common missense mutations in the TP53 gene disrupt the …

Stability and localization of p53 is essential for its tumor suppressor function. Ubiquitination
by the E3 ubiquitin ligase Mdm2 is the major regulatory mechanism of p53, which induces …

TP53 is probably the most extensively studied tumour-suppressor gene, and patients with
TP53 mutations are known to have a poor outcome. However, inconsistencies in the …

Approximately half of all colorectal cancers show p53 (TP53) gene mutations, with higher
frequencies observed in distal colon and rectal tumors and lower frequencies in proximal …

There are now reports of nearly 250 independent germline TP53 (p53) mutations in over
100 publications. Such mutations are typically associated with Li‐Fraumeni or Li‐Fraumeni …

Abstract The TP53 gene (p53) is found altered in breast carcinomas in approximately 20–
40% of all cases depending on tumor size and stage of the disease. It seems to be an early …

The tumour suppressor gene p53 is extensively studied for its importance in cancer. In its
active conformation, p53 is tetrameric and one domain–the tetramerization domain–permits …

Although DNA damaging agents have revolutionized chemotherapy against solid tumors, a
narrow therapeutic window combined with severe side effects has limited their broader use …